About fennec pharmaceuticals - FENC
Fennec Pharmaceuticals, Inc. is a specialty pharmaceutical company. It focuses on the development and commercialization of PEDMARK to reduce the risk of platinum-induced ototoxicity in pediatric patients. The company was founded by Orest W. Blaschuk on September 3, 1996 and is headquartered in Durham, NC.
FENC At a Glance
Fennec Pharmaceuticals, Inc.
Research Triangle Park
Durham, North Carolina 27709
| Phone | 1-919-636-4530 | Revenue | 47.54M | |
| Industry | Pharmaceuticals: Major | Net Income | -436,000.00 | |
| Sector | Health Technology | 2024 Sales Growth | 123.687% | |
| Fiscal Year-end | 12 / 2025 | Employees | 32 | |
| View SEC Filings |
FENC Valuation
| P/E Current | N/A |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | N/A |
| Price to Sales Ratio | 3.515 |
| Price to Book Ratio | N/A |
| Price to Cash Flow Ratio | 6.19 |
| Enterprise Value to EBITDA | 61.735 |
| Enterprise Value to Sales | 3.335 |
| Total Debt to Enterprise Value | 0.114 |
FENC Efficiency
| Revenue/Employee | 1,485,562.50 |
| Income Per Employee | -13,625.00 |
| Receivables Turnover | 3.69 |
| Total Asset Turnover | 1.324 |
FENC Liquidity
| Current Ratio | 6.377 |
| Quick Ratio | 6.224 |
| Cash Ratio | 3.849 |
FENC Profitability
| Gross Margin | 93.302 |
| Operating Margin | 5.402 |
| Pretax Margin | -0.149 |
| Net Margin | -0.917 |
| Return on Assets | -1.214 |
| Return on Equity | N/A |
| Return on Total Capital | -3.575 |
| Return on Invested Capital | -2.879 |
FENC Capital Structure
| Total Debt to Total Equity | N/A |
| Total Debt to Total Capital | 148.143 |
| Total Debt to Total Assets | 40.202 |
| Long-Term Debt to Equity | N/A |
| Long-Term Debt to Total Capital | 148.127 |